Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855695 · ClinicalTrials.gov registry record · Phase 1
Avo In R/R And Previously Untreated MCL
A Phase 1 study of Mantle Cell Lymphoma and Refractory Lymphoma, sponsored by Austin I Kim.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 3
- Study locations
NCT04855695 is a Phase 1 study of Mantle Cell Lymphoma and Refractory Lymphoma that is actively recruiting participants, run by Austin I Kim. The registered enrollment target is 72 participants, below the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (30% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04855695, a Phase 1 study of Mantle Cell Lymphoma and Refractory Lymphoma, is actively recruiting participants, sponsored by Austin I Kim.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzumab
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Acalabrutinib
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04855695
The ClinicalTrials.gov registry entry for NCT04855695 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (30% lower). The listed sponsor is Austin I Kim, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT04855695 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT04855695 about?
NCT04855695 is a clinical study titled "Avo In R/R And Previously Untreated MCL". This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obin...
What is the current status of trial NCT04855695?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-07-02. Estimated completion is 2027-12-31.
What conditions does trial NCT04855695 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Refractory Lymphoma.
What interventions are being tested in trial NCT04855695?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT04855695?
This trial is sponsored by Austin I Kim, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04855695 being conducted?
This trial has 3 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.